ESR1, which was less strongly associated with ATAD2 expression, was significant in the adjusted model only in endometrial cancer (p = 0.016) and glioblastoma (p<0.001), not in ovarian or breast cancer. This evidence concerns the gene ATAD2 and breast cancer.